Society for Immunotherapy of Cancer announces 2026 annual award recipients

Stephenson Global Pancreatic Cancer Research Institute awards $6.7M to accelerate pancreatic cancer research

The Stephenson Global Pancreatic Cancer Research Institute announced the recipients of the 2026 Stephenson Global Scholar Grants.

August 07, 2026

Vol.52 No.31

In Brief

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Dana-Farber Cancer Institute’s Department of Pathology, in collaboration with Brigham and Women’s Hospital, has received renewed funding for the Ruth L. Kirschstein NRSA Institutional Research Training Grant from the NCI, providing resources for pathology residents, clinical fellows, and PhD-trained scientists pursuing research careers in cancer pathology.

August 07, 2026

Vol.52 No.31

Clinical Trials & Tribulations

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The recent retraction of the LungTIME-C01 randomized trial evaluating chrono-modulated immunotherapy in non-small cell lung cancer has ignited a vigorous debate regarding the promise of cancer chronotherapy.

July 31, 2026

Vol.52 No.30

By Zachary S. Buchwald and Michael C. Lowe

In Brief

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

The V Foundation for Cancer Research, a top-rated cancer research charity, announced $11.2 million in funding awarded to 14 scientists through its 2026 Breaking Barriers in Cancer Research Award program.

July 24, 2026

Vol.52 No.29

In Brief

Fred Hutch Cancer Center announces 2026 Evergreen Fund awardees

Eight researchers at Fred Hutch Cancer Center will receive a total of $975,000 for research projects as part of Fred Hutch’s Evergreen Fund, an internal grant program designed to advance translational discoveries to a commercially viable stage.

July 17, 2026

Vol.52 No.28

News Analysis

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

July 10, 2026

Vol.52 No.27

By Jacquelyn Cobb

Society for Immunotherapy of Cancer announces 2026 annual award recipients

YOU MAY BE INTERESTED IN

Stephenson Global Pancreatic Cancer Research Institute awards $6.7M to accelerate pancreatic cancer research

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

Fred Hutch Cancer Center announces 2026 Evergreen Fund awardees

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Renew today!

Subscriber content

Never miss an issue!

Login

Society for Immunotherapy of Cancer announces 2026 annual award recipients

YOU MAY BE INTERESTED IN

Stephenson Global Pancreatic Cancer Research Institute awards $6.7M to accelerate pancreatic cancer research

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

Fred Hutch Cancer Center announces 2026 Evergreen Fund awardees

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Never miss an issue!

Login

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.